

ABSTRACT OF THE DISCLOSURE

COMBINATION THERAPY FOR TYPE II DIABETES OR SYNDROME X

5 This invention provides methods of using a pharmacological combination of a
biguanide agents, such as metformin, and one or more PTPase inhibiting agents
and, optionally, one or more sulfonylurea agents, including glyburide, glyburide,
glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a
mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin
10 resistance or hyperglycemia. Further included in this invention is a method of
modulating blood glucose levels in a mammal utilizing the combination of one or
more PTPase inhibiting agents and one or more sulfonylurea agents.